Skip to main content
    N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    CONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ

    $2.01
    -0.05 (-2.66%)

    Market Cap: $163.54M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Niagen Bioscience, Inc. (NAGE) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Niagen Bioscience (NAGE) trades at 42.2x trailing earnings and 1.3x sales. Its P/S of 1.3x is below its 5-year median of 2.4x. Its forward P/E is 41.1x. The median P/E across 7 similar companies is 11.1x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 2.7% higher over the next year.

    MultipleValue
    P/E (trailing)42.2x
    Forward P/E41.1x
    Price to sales1.3x
    Price to book1.9x
    EV/EBITDA8.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 71.1% below 4.5x and its P/B is 74.7% below 7.5x.

    MultipleCurrent5-year median10-year median
    P/S1.3x2.4x4.5x
    P/B1.9x5.5x7.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 108 to 114 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.3x in 2023 to 6.0x in 2018.

    Year endPriceP/EP/SP/B
    2025$6.3637.9x3.9x7.0x
    2024$5.3145.9x4.1x9.4x
    2023$1.43N/A1.3x3.8x
    2022$1.68N/A1.6x5.5x
    2021$3.74N/A3.7x7.2x
    2020$4.80N/A4.9x15.2x
    2019$4.31N/A5.3x9.2x
    2018$3.43N/A6.0x5.7x
    2017$5.88N/AN/AN/A
    2016$3.31N/A5.7x10.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NAGE

    What is NAGE's forward P/E ratio?

    Niagen Bioscience has a forward P/E ratio of 41.1x.

    Is NAGE stock overvalued?

    GNG's valuation label for NAGE is Fairly valued. Its P/E of 42.2x compares with a median of 11.1x across 7 similar companies.

    What is NAGE's price to sales ratio?

    Niagen Bioscience has a price to sales ratio of 1.3x.